PE20050725A1 - Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos - Google Patents

Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos

Info

Publication number
PE20050725A1
PE20050725A1 PE2004000736A PE2004000736A PE20050725A1 PE 20050725 A1 PE20050725 A1 PE 20050725A1 PE 2004000736 A PE2004000736 A PE 2004000736A PE 2004000736 A PE2004000736 A PE 2004000736A PE 20050725 A1 PE20050725 A1 PE 20050725A1
Authority
PE
Peru
Prior art keywords
indol
rings
optionally
monostituted
sulfonamide
Prior art date
Application number
PE2004000736A
Other languages
English (en)
Inventor
Zueras Alberto Dordal
Vidal Ramon Merce
Soler Xavier Codony
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of PE20050725A1 publication Critical patent/PE20050725A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 5-INDOLSULFONAMIDAS DE FORMULA (I), EN DONDE R1 ES UN RADICAL -NR8R9 O UN RADICAL CICLOALIFATICO DE 5 A 6 MIEMBROS OPCIONALMENTE SATURADO Y MONOSUSTITUIDO CON AL MENOS UN HETEROATOMO, EL CUAL PUEDE CONDENSARSE CON UN SISTEMA ANULAR CICLOALIFATICO; R2, R3, R4, R5, R6 Y R7, IDENTICOS O DIFERENTES, SON H, ALQUILO(C1-C6) LINEAL O RAMIFICADO; A ES UN SISTEMA DE ANILLO AROMATICO MONO O POLICICLICO OPCIONALMENTE MONOSUSTITUIDO, DE 5 A 6 MIEMBROS, QUE PUEDEN ENLAZARSE VIA ALQUILENO, ALQUENILENO O ALQUINILENO OPCIONALMENTE MONOSUSTITUIDO, Y AL MENOS UN DE LOS ANILLOS CONTIENE UN HETEROATOMO; W ES UN ENLACE SENCILLO ENTRE LOS DOS ANILLOS, CH2, O, S O NR14; m ES 0,1,2,3 O 4 Y m1 ES 1 O 2. SON COMPUESTOS PREFERIDOS: N-[1-(2-PIRROLIDIN-1-IL-ETIL)-1H-INDOL-5-IL]NAFTALENO-2-SULFONAMIDA, N-[1-(2-DIMETILAMINOETIL)-1H-INDOL-5-IL]-5-CLORO-3-METILBENZO[b]TIOFENO-2-SULFONAMIDA, 4-FENOXI-N-(1-(3-(PIPERIDINIL-1-IL)PROPIL)-1H-INDOL-5-IL)BENCENOSULFONAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE OBTENCION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS MUESTRAN AFINIDAD POR EL RECEPTOR 5TH6, POR LO QUE SON UTILES EN LA PREVENCION Y TRATAMIENTO DE DESORDENES RELACIONADOS CON LA INGESTION DE ALIMENTOS, REGULACION DEL APETITO, TRANSTORNOS GASTROINTESTINALES Y DEL SISTEMA NERVIOSO CENTRAL
PE2004000736A 2003-07-30 2004-08-02 Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos PE20050725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200301805A ES2222827B1 (es) 2003-07-30 2003-07-30 Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.

Publications (1)

Publication Number Publication Date
PE20050725A1 true PE20050725A1 (es) 2005-11-16

Family

ID=34130539

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000736A PE20050725A1 (es) 2003-07-30 2004-08-02 Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos

Country Status (22)

Country Link
US (1) US20070032520A1 (es)
EP (1) EP1648445B1 (es)
JP (1) JP2007500165A (es)
KR (1) KR20060066710A (es)
CN (1) CN100558355C (es)
AR (1) AR045156A1 (es)
AT (1) ATE432699T1 (es)
AU (1) AU2004262485A1 (es)
BR (1) BRPI0413110A (es)
CA (1) CA2533976A1 (es)
DE (1) DE602004021384D1 (es)
EC (1) ECSP066325A (es)
ES (2) ES2222827B1 (es)
IL (1) IL172891A0 (es)
MX (1) MXPA06001159A (es)
NO (1) NO20060865L (es)
PE (1) PE20050725A1 (es)
PT (1) PT1648445E (es)
RU (1) RU2006105779A (es)
TW (1) TW200504014A (es)
WO (1) WO2005013977A1 (es)
ZA (1) ZA200600422B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
ES2246721B1 (es) * 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
EP1856075A1 (en) 2005-01-25 2007-11-21 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
DE102007007751A1 (de) * 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
ATE495737T1 (de) 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
IN2012DN00471A (es) 2009-06-29 2015-06-05 Agios Pharmaceuticals Inc
KR101593099B1 (ko) * 2009-10-27 2016-02-11 엘지디스플레이 주식회사 액정표시장치용 어레이 기판 및 그 제조방법
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) * 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
US3583622A (en) * 1969-03-21 1971-06-08 Robert Frank Graeff Stapler
US4291486A (en) * 1979-11-30 1981-09-29 Farnam Companies, Inc. Rodent trap
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
CA2433351A1 (en) * 2001-01-30 2002-08-08 Eli Lilly And Company Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
WO2003027095A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
ES2222827B1 (es) 2006-03-01
EP1648445B1 (en) 2009-06-03
IL172891A0 (en) 2006-06-11
BRPI0413110A (pt) 2006-10-03
TW200504014A (en) 2005-02-01
ATE432699T1 (de) 2009-06-15
PT1648445E (pt) 2009-09-03
AU2004262485A1 (en) 2005-02-17
CA2533976A1 (en) 2005-02-17
DE602004021384D1 (de) 2009-07-16
ES2222827A1 (es) 2005-02-01
MXPA06001159A (es) 2006-04-24
KR20060066710A (ko) 2006-06-16
JP2007500165A (ja) 2007-01-11
NO20060865L (no) 2006-02-22
US20070032520A1 (en) 2007-02-08
RU2006105779A (ru) 2007-09-20
AR045156A1 (es) 2005-10-19
CN100558355C (zh) 2009-11-11
EP1648445A1 (en) 2006-04-26
ECSP066325A (es) 2006-08-30
WO2005013977A1 (en) 2005-02-17
ES2327847T3 (es) 2009-11-04
CN1832740A (zh) 2006-09-13
ZA200600422B (en) 2007-03-28

Similar Documents

Publication Publication Date Title
PE20050725A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
MY141476A (en) 5ht2c receptor modulators
DE60025604D1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
PA8493701A1 (es) Compuestos para tratar la obesidad
UY25180A1 (es) Derivados de carboxamidotiazoles, su preparación, composiciones farmacéuticas que los contienen.
ATE422887T1 (de) Kondensierte heterozyklische verbindungen
GT199800046A (es) Compuestos de pirazina.
MXPA05013366A (es) Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
PA8491901A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
HUP0400240A2 (hu) Szubsztituált oxazolidinonszármazékok és más hatóanyagok kombinációi és ezeket tartalmazó gyógyszerkészítmények
HUP0401783A2 (hu) 3,4-Diszubsztituált ciklobutén-1,2-dionok mint CXC-kemokin receptor ligandumok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ATE383339T1 (de) Amin-derivate zur behandlung von apoptosis
ECSP056164A (es) Compuestos utiles para el tratamiento de enfermedades
DK0561941T3 (da) N-Substituerede lactamer anvendelige som cholecystokinin-antagonister
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
BR0308338A (pt) Derivados de nitrosodifenilamina e seu uso farmacêutico contra patologias de estresse oxidativo
BRPI0411998A (pt) moduladores delta-opióides tricìclicos
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
HUP0303270A2 (hu) Antidepresszáns hatású izoxazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO20091832L (no) Indoler som virker via reseptorantagonister

Legal Events

Date Code Title Description
FC Refusal